KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Long-Term Survival Outcomes of NCRT With Surgery vs Surgery With Adjuvant Therapy for ESCC: A Single-Center Prospective Phase 3 Randomized Clinical Trial.

Wenwu He, Zhiyu Li, Qin Xie, Yongtao Han, Lin Peng, Chenghao Wang, Kangning Wang, Guangyuan Liu, Haojun Li, Qiang Zhou, Jialong Li, Huan Zhang, Wenguang Xiao, Qiang Fang, Yan Miao, Xuefeng Leng

JAMA Netw Open 9(1) e2550307

PMID41490111
PMCIDPMC12771256
DOI10.1001/jamanetworkopen.2025.50307
发表日期2026-01-06
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

IMPORTANCE: The optimal treatment strategy for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. Neoadjuvant chemoradiotherapy (NCRT) followed by surgery and surgery with adjuvant therapy (AT) are commonly used approaches. OBJECTIVES: To compare the long-term survival outcomes, safety, and pathological benefits of NCRT followed by surgery vs surgery with AT in patients with locally advanced ESCC, and to evaluate the survival impact of pathological complete response (pCR) in the NCRT subgroup. DESIGN, SETTING, AND PARTICIPANTS: This prospective, randomized, open-label phase 3 trial was conducted at Sichuan Cancer Hospital, China, between January 2018 and April 2020. Eligible patients were aged 18 to 75 years; had histologically confirmed, resectable, locally advanced thoracic ESCC, staged as cT1N+M0 or cT2-4aNxM0; were expected to survive more than 6 months; and had adequate organ function. Key exclusion included prior malignant neoplasms, distant or cervical lymph node metastasis, contraindications to surgery, and prior gastrectomy precluding reconstruction. Data were analyzed April to December 2024. INTERVENTIONS: Patients in the NCRT group received intensity-modulated radiotherapy (40 Gy in 20 fractions) with concurrent paclitaxel and carboplatin followed by surgery. Patients in the AT group received an adjuvant chemoradiotherapy regimen designed by a multidisciplinary team. MAIN OUTCOMES AND MEASURES: The primary end point was overall survival (OS). Secondary end points included disease-free survival (DFS), pathological outcomes, treatment-related toxic effects, and perioperative complications. RESULTS: A total of 254 patients were initially enrolled; after exclusions and randomization, 118 patients in the NCRT group (median [IQR] age, 62 [54-66] years; 102 [86.4%] male) and 112 patients in the AT group (median [IQR] age, 63 [55-66] years; 97 [86.6%] male) were included in the analysis. After a median (IQR) follow-up of 59.1 (54.4-65.9) months, there were no significant differences in OS or DFS between the groups. The 5-year OS rates were 59.2% (95% CI, 51.0%-68.8%) for the NCRT group and 59.6% (95% CI, 51.2%-69.5%) for the AT group (hazard ratio [HR], 1.01; 95% CI, 0.67-1.51; P = .97). The 5-year DFS rates were 53.1% (95% CI, 44.7%-63.1%) and 56.5% (95% CI, 47.9%-66.7%), respectively (HR, 1.13; 95% CI, 0.77-1.68; P = .53). Subgroup analysis showed that patients achieving pCR in the NCRT group had significantly improved survival outcomes, with a 5-year OS rate of 76.5% (95% CI, 63.5%-92.1%) compared with 52.1% (95% CI, 42.4%-64.1%) for non-pCR patients (HR, 0.39; 95% CI, 0.18-0.82; P = .01). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, there were no differences in OS or DFS for patients treated with NCRT followed by surgery or surgery with AT. However, for the patients who achieved pCR with NCRT, there were significant advantages, with markedly improved long-term outcomes. Nevertheless, neoadjuvant chemoradiotherapy did not benefit all patients; for those less likely to respond, the combination of surgery with postoperative AT remains a reasonable strategy. These findings show that it may not be appropriate to universally recommend neoadjuvant chemoradiotherapy for all patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06775652.

KM 提取结果

3 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2.. Overall Survival and Disease-Free Survival Among Neoadjuvant Chemoradiotherapy (NCRT) and Adjuvant Therapy (AT) Groups HR indicates hazard ratio.

A

Overall survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Disease-free survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
KM Figure2 个面板

Figure 3

Figure 3.. Overall and Disease-Free Survival in Neoadjuvant Chemoradiotherapy (NCRT) Subgroups (Pathologic Complete Response [pCR] and no pCR) Compared With the Adjuvant Therapy (AT) Group

A

Overall survival

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 3 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Disease-free survival

Figure 3 · Panel B

complete 待 EXE 对齐 预期 3 条 已提取 3 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
KM Figure2 个面板

Figure 4

Figure 4.. Overall and Disease-Free Survival Among Patients in the Neoadjuvant Chemoradiotherapy (NCRT) and Adjuvant Therapy (AT) Groups With cTNM III-IVA Disease HR indicates hazard ratio.

A

Overall survival

Figure 4 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Disease-free survival

Figure 4 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Study Flow Diagram ESCC indicates esophageal squamous cell carcinoma. a Due to health issues, 11 patients switched to oral tegafur, 6 interrupted chemotherapy, and 3 interrupted radiotherapy.
非 KM Figure